Posted by Michael Wonder on 06 Nov 2023
AviadoBio announces FDA IND clearance and fast track designation for AVB-101 for the treatment of frontotemporal dementia with progranulin mutations
6 November 2023 - AVB-101 is an investigational gene therapy delivered as a one time infusion directly to the brain, enabling distribution to brain areas affected by frontotemporal dementia while limiting systemic exposure.
AviadoBio today announced that the US FDA has cleared the investigational new drug application for AVB-101 to be studied in people with frontotemporal dementia with mutations in the progranulin gene.
